The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the regulation of blood pressure and volume homeostasis, promoting critical structural changes in every component of the cardiovascular system, including the heart and blood vessels. Consequently, the RAAS is a crucial therapeut...
| Publicado en: | Heart Failure Reviews Vol. 25; no. 1; pp. 31 - 43 |
|---|---|
| Autores principales: | , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Jan2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141414563&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 141414563 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 13824147 OG1 jtl: Heart Failure Reviews issn: 13824147 maglogo: N pubinfo: dt: Jan2020 vid: 25 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 141414563 141414563 NLM31512149 141414563 10.1007/s10741-019-09855-5 NLM31512149 141414563 ppf: 31 ppct: 12 formats: tig: atl: The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. aug: au: Pugliese, Nicola Riccardo Masi, Stefano Taddei, Stefano affil: Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy sug: subj: Renin-Angiotensin System Drug Effects Heart Failure Drug Therapy Heart Failure Prevention and Control Hypertension Drug Therapy Antihypertensive Agents Therapeutic Use Human Stroke Volume Drug Effects Angiotensin-Converting Enzyme Inhibitors Therapeutic Use Heart Failure Physiopathology Angiotensin II Type I Receptor Blockers Therapeutic Use Hypertension Physiopathology Blood Pressure Drug Effects Clinical Trials Aldosterone Antagonists Therapeutic Use ab: The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in the regulation of blood pressure and volume homeostasis, promoting critical structural changes in every component of the cardiovascular system, including the heart and blood vessels. Consequently, the RAAS is a crucial therapeutic target for several chronic diseases of the cardiovascular system, spanning from arterial hypertension (AH) to heart failure (HF). AH represents a leading risk factor for the development of symptomatic HF, particularly with left ventricle (LV) preserved ejection fraction (HFpEF). LV diastolic dysfunction and cardiac remodelling are the first discernible manifestations of heart disease in patients with AH. Typically, AH develops many years before the diagnosis of overt HF, providing a therapeutic target for preventive strategies. Treatment of AH is based on different classes of antihypertensive drugs, which show differences in their capacity to prevent the evolution towards HF. The blockers of the RAAS are effective drugs to treat AH and prevent HF with reduced ejection fraction (HFrEF), but the evidence of the potential benefits in patients with HFpEF remains limited. In this review, the authors summarise data from several clinical trials of HFpEF and HFrEF, focusing on the mechanisms leading the transition from AH to HF and late complications. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|